Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2017-07-21
|
anetumab ravtansine (BAY 94-9343) |
mesothelioma |
2 |
Bayer Healthcare (Germany) MorphoSys (Germany) Immunogen (USA - MA) |
Cancer - Oncology |
2017-07-21
|
JX-594/TG6006 (Pexa-Vec -pexastimogene devacirepvec) |
hepatocellular carcinoma (HCC) |
3 |
Transgene (France) Sillajen (Republic of Korea) |
Cancer - Oncology |
2017-07-19
|
IFN alpha Kinoid |
dermatomyositis |
2a |
Neovacs (France) |
Autoimmune diseases - Dermatological diseases - Rare diseases |
2017-07-19
|
Macuneos (formerly BIO201) |
age related macular degeneration (AMD) |
1-2 |
Biophytis (France) |
Ageing diseases - Ophtalmological diseases |
2017-07-18
|
EB-101 (gene corrected skin grafts) |
dystrophic epidermolysis bullosa, |
3 |
Abeona Therapeutics (USA - NY) |
Rare diseases - Genetic diseases - Dermatological diseases |
2017-07-17
|
STRO-001 |
non-Hodgkin lymphoma, multiple myeloma |
preclinical |
Sutro Biopharma (USA - CA) |
Cancer - Oncology |
2017-07-17
|
WVE-120101 |
Huntington’s disease |
1-2 |
Wave LIfe Sciences (USA - MA) |
Rare diseases - Genetic diseases - Neurodegenerative diseases |
2017-07-17
|
WVE-120102 |
Huntington's disease |
1-2 |
Wave LIfe Sciences (USA - MA) |
Rare diseases - Genetic diseases - Neurodegenerative diseases |
2017-07-17
|
flotetuzumab - MGD006 |
relapsed or refractory acute myeloid leukemia |
1 |
Macrogenics (USA - Md) Servier (France) |
Cancer - Oncology |
2017-07-15
|
RNAntibody® technology |
|
preclinical |
Curevac (Germany) |
Cancer - Oncology - Infectious diseases |
2017-07-13
|
voretigene neparvovec - SPK-RPE65 |
inherited retinal dystrophy (IRD) caused by RPE65 mutations - Leber Congenital Amaurosis (LCA) 2 |
3 |
Spark Therapeutics (USA - PA) |
Rare diseases - Genetic diseases - Ophtalmological diseases |
2017-07-12
|
ABX464 |
inflammatory bowel disease |
preclinical |
Abivax (France) |
Inflammatory diseases - Gastrointestinal diseases |
2017-07-11
|
Praxbind® (idarucizumab) |
specific antidote for Pradaxa® (dabigatran etexilate) - reversion of the anticoagulant effect of dabigatran due to uncontrolled life-threatening bleeding requiring urgent intervention or a need to undergo an emergency surgery/urgent invasive procedure. |
3 |
Boehringer Ingelheim (Germany) |
Cardiovascular diseases - Cerebrovascular diseases |
2017-07-11
|
Austedo™ (SD-809 - deutetrabenazine) |
chorea associated with Huntington disease |
3 |
Teva Pharmaceutical Industries (Israel) |
Neurodegenerative diseases - Rare diseases |
2017-07-11
|
AAV5-hFIX - AMT-060 |
hemophilia B |
1-2 |
uniQure (The Netherlands) Chiesi Farmaceutici (Italy) |
Genetic diseases- Hematological diseases - Rare diseases |
2017-07-10
|
ExOlin® |
type 1 diabetes, type 2 diabetes |
|
Defymed (France) |
Metabolic diseases |
2017-07-10
|
MDG1011 |
advanced hematological diseases, namely acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and multiple myeloma (MM) |
1-2 |
Medigene (Germany) |
Cancer - Oncology |
2017-07-10
|
NKTR-358 |
|
preclinical |
Nektar Therapeutics (USA - CA) |
Autoimmune diseases – Inflammatory diseases |
2017-07-10
|
Cabometyx™ (cabozantinib) with Opdivo® (nivolumab) alone or in combination with Yervoy® (ipilimumab) |
previously untreated, advanced or metastatic renal cell carcinoma |
3 |
Exelixis (USA - CA) BMS (USA - NY) |
Cancer - Oncology |
2017-07-08
|
Translarna™ (ataluren) |
nonsense mutation Duchenne Muscular Dystrophy (nmDMD) |
3 |
PTC Therapeutics (USA - NJ) |
Rare diseases - Neuromuscular diseases |